Sovaldi + Olysio + ribavirin Harvoni + ribavirin. Sovaldi + ribavirin Viekira Pak
|
|
- Ruby Lester
- 6 years ago
- Views:
Transcription
1 Hepatitis Prior Authorization Request CVS Caremark administers the specialty pharmacy benefit plan for the patient identified. This patient s benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. Please respond below and fax this form to Assurant Health at If you have questions regarding the prior authorization, please contact Assurant Health Rx ext Patient s Name: Date: Patient s ID: Patient s Date of Birth: Physician s Name: Specialty: NPI#: Physician Office Telephone: Physician Office Fax: Generic ribavirin is the preferred product when prescribing Moderiba or Ribasphere RibaPak; and Harvoni and Sovaldi are the preferred regimens when prescribing a Viekira Pak or Technivie regimen for your patient s health plan. Please attach all necessary lab(s) or clinical for supporting documentation. 1. What is the prescribed drug regimen for patient's course of treament? Harvoni monotherapy Sovaldi + Olysio + ribavirin Harvoni + ribavirin Sovaldi + ribavirin Viekira Pak Victrelis + PEG-IFN + ribavirin Viekira Pak + ribavirin Pegasys monotherapy Sovaldi + PEG-IFN + ribavirin Peg Intron monotherapy Olysio + PEG-IFN + ribavirin PEG-IFN + ribavirin Sovaldi + Olysio Daklinza + Sovaldi Technivie Technivie + ribavirin Other Specify product if ribavirin is being prescribed: generic ribavirirn Moderiba Ribasphere RibaPak Other Complete the following section if brand ribavirin (Moderiba or Ribasphere RibaPak) is being prescribed. If not, continue to question #7. 2. Is the prescriber willing to switch to generic ribavirin? Yes No If Yes, skip to #7 (if applicable) and fax a new prescription to Does the patient have a paid claim for the requested branded medication (i.e., Moderiba or Ribasphere RibaPak) in the previous 30 days? Yes No If Yes, document therapy start date and approval # and skip to #7 (if applicable): 4. Has the patient failed treatment with generic ribavirin due to an intolerable adverse event (example: rash, nausea, vomiting)? Yes No 5. Was the intolerable adverse event attributed to an inactive ingredient of the generic medication? Yes No 6. Was this documented in the patients chart? Yes No Action Required: Documentation is required for approval. Provide SPECIFIC and DETAILED chart documentation or MedWatch form of this trial and failure included in adverse reaction. 7. What is the patient's BASELINE viral load? Date of lab work: Action Required: Attach supporting documentation. Page 1 of 5
2 8. Indicate the SPECIFIC date patient will or has start(ed) this course of therapy? DO NOT USE "ASAP" (MM/DD/YYYY) 9. Indicate planned duration of therapy: weeks If Harvoni is being prescribed, will 8 weeks of treatment with Harvoni be adequate for this patient? Yes No Indicate current week of treatment (if applicable): Action Required: Attach documentation of treatment plan including regimen and duration. 10. What is the ICD code? 11. What is the diagnosis? Chronic hepatitis C Hepatitis B, including HDV Co-infection (for Pegasys and PegIntron only) - skip to Section F Acute hepatitis C (Pegasys, PegIntron and ribavirin only) - no further questions Chronic myeloid leukemia, CML (Pegasys and Peg Intron only) - no further questions Giant cell tumor of the bone (Pegasys only) - no further questions Other 12. What is the patient's genotype? If genotype 1, specify the subtype: 1a 1b Mixed Unknown 13. What is the prescriber's specialty? 14. What is the METAVIR fibrosis score? Unavailable 15. Provide previous treatment regimen(s), outcome and the length of therapy. If new to therapy, mark: Not applicable (treatment naïve), skip to #17 Outcome: Relapser Nonresponder Outcome: Relapser Nonresponder Outcome: Relapser Nonresponder 16. Has the patient failed treatment with a HCV protease inhibitor (eg, Incivek, Olysio, Victrelis, paritaprevir) despite adequate dosing and duration of therapy? Yes No 17. Does the patient have any of the following? Indicate below or mark "None of the above." Cirrhosis HIV co-infection Recurrent HCV infection post liver transplantation Decompensated liver disease/moderate to severe hepatic impairment (Child Turcotte Pugh [CTP] class B or C) None of the above HIV Co-Infection 18. Is the patient currently receiving antiretroviral therapy (ART)? If Yes, skip to #20 Yes No 19. What is the patient's CD4 count? cells/mm Will the patient be receiving treatment with any of the following: Indicate below or mark "None of the above." efavirenz (Sustiva, Atripla) etravirine (Intelence) Maraviroc darunavir (Prezista, Prezcobix) nevirapine (Viramune) tipranavir (Aptivus) List continues on following page. rilpivirine (Edurant, Complera) lopinavir/ritonavir (Kaletra) Ritonavir-boosted saquinavir Ritonavir-boosted lopinavir Fosamprenavir Ritonavir-boosted tipranavir Elvitegravir/cobicistat/tenofovir/emtricitabine (Stribild) Other HIV protease inhibitors (eg, atazanavir [Reyataz, Evotaz], fosamprenavir [Lexiva], saquinavir [Invirase] None of the above Page 2 of 5
3 Complete the following section(s) based on the prescribed regimen and complete section I, if applicable. Section A: Harvoni (with or without ribavirin) 21. Will Harvoni be used with other drugs containing sofosbuvir, including Sovaldi? Yes No 22. Does the patient have decompensated cirrhosis? Yes No 23. Is the patient ineligible to receive ribavirin? Yes No If Yes, document reason for ineligibility: 24. Does the patient have documented anemia? Yes No If No, no further questions. 25. What is the patient s baseline hemoglobin level? g/dl Section B: Viekira (with or without ribavirin) 25. Does the patient have a paid claim for Viekira Pak in the previous 30 days? Yes No If Yes, document therapy start date and approval # and skip to #29: 26. Is the prescriber willing to switch to one of the preferred regimens? If Yes, indicate regimen, fax a new prescription to and continue to appropriate section below. Yes, Harvoni regimen Specify drug regimen: Yes, Sovaldi regimen Specify drug regimen: No, continue to request Viekira Pak regimen Other 27. Has the patient had an inadequate treatment response to a previous trial of Harvoni or Sovaldi? Yes No Action Required: If Yes, attach supporting documentation and skip to # Does the patient have a documented contraindication, intolerance or confirmed adverse event to Harvoni or Sovaldi? Yes No Action Required: If Yes, attach supporting documentation. 29. Will Viekira Pak be given in combination with any of the following drugs that are highly dependent on CYP3A for clearance, strong inducers of CYP3A or CYP2C8, or strong inhibitors of CYP2C8? Indicate below or mark "None of the above." alfuzosin HCl (Uroxatral) lovastatin (Advicor, Altoprev, Mevacor) carbamazepine (Carbatrol, Epitol, Equetro, Tegretol) simvastatin (Simcor, Vytorin, Zocor) phenytoin (Dilantin, Phenytek) pimozide (Orap) phenobarbital (Luminal) efavirenz (Atripla, Sustiva) gemfibrozil (Lopid) triazolam (Halcion) rifampin (Rifadin, Rifamate, Rifater, Rimactane) orally administered midazolam St. John s wort ergot derivatives (ergotamine [Cafergot, Ergomar, Medihaler, Migergot, Wigraine, Wigrettes], dihydroergotamine [D.H.E. 45, Migranal], ergonovine [Ergotrate], methylergonovine [Methergine]) ethinyl estradiol-containing medications (eg, Lo Loestrin Fe, Ortho Tri-Cyclen Lo, Ortho Evra, NuvaRing) sildenafil or Revatio when used for the treatment of pulmonary arterial hypertension (PAH) None of the above Section C: Olysio + PEG-IFN + Ribavirin In addition, if patient is currently on therapy, section I must be completed. 30. If patient's genotype is 1a, is the NS3 Q80K polymorphism present? Yes No Unknown Action Required: Attach Q80K polymorphism testing results. Section D: Sovaldi + Ribavirin 31. Is the request for a patient with hepatocellular carcinoma awaiting liver transplantation? Yes No If No, skip to # Does the patient meet the MILAN criteria? Indicate below or mark "None of the above." Tumor size 5cm or less in diameter with single hepatocellular carcinomas OR 3 tumor nodules or less, each 3cm or less in diameter with multiple tumors No extrahepatic manifestations of the cancer or evidence of vascular invasion of tumor None of the above Page 3 of 5
4 33. If patient's genotype is 1, does the patient have documented IFN ineligibility? Yes No If Yes, document reason for IFN ineligibility: Section E: Victrelis + PEG-IFN + Ribavirin (Only required for continuation of therapy) In addition, if patient is currently on therapy, section I must be completed. 34. Was the patient poorly interferon responsive (ie, less than 1.0-log 10 decline in viral load (HCV-RNA]) at week 4 of treatment? If Yes, no further questions in section. Yes No Not applicable 35. With prior therapy with PEG-IFN and ribavirin, did the patient have less than 2-log 10 drop in viral load (HCV- RNA) after 12 weeks of treatment (ie, null responder)? Yes No Not applicable Section F: Pegasys/PegIntron - Hepatitis B Virus Infection 36. How long has the patient received Pegasys/PegIntron for the treatment of hepatitis B? weeks If request is for continuation of therapy, no further questions. 37. Has the patient been HBsAg positive for at least 6 months? Yes No 38. What is the patient's serum HBV-DNA? copies/ml or IU/mL 39. What is the patient s HBeAg type? Negative Positive 40 Does the patient have liver biopsy showing chronic hepatitis with moderate to severe necroinflammation? If Yes, no further questions Yes No 41. Does the patient have persistent or intermittently elevated ALT greater than 2x the upper limit of normal? Yes No Section G: Technivie (with or without ribavirin) 42. Does the patient have a paid claim for Technivie in the previous 30 days? Yes No If Yes, document therapy start date and approval # and skip to #46: 43. Is the prescriber willing to switch to one of the preferred regimens? If Yes, indicate regimen, fax a new prescription to and continue to appropriate section below. Yes, Harvoni regimen Specify drug regimen: Yes, Sovaldi regimen Specify drug regimen: No, continue to request a Technivie regimen Other 44. Has the patient had an inadequate treatment response to a previous trial of Harvoni or Sovaldi? Yes No Action Required: If Yes, attach supporting documentation and skip to # Does the patient have a documented contraindication, intolerance or confirmed adverse event to Harvoni or Sovaldi? Yes No Action Required: If Yes, attach supporting documentation. 46. Will Technivie be given in combination with any of the following drugs that are highly dependent on CYP3A for clearance or that are moderate or strong inducers of CYP3A? alfuzosin HCl (Uroxatral) lovastatin (Advicor, Altoprev, Mevacor) List continues on following page. carbamazepine (Carbatrol, Epitol, Equetro, Tegretol) simvastatin (Simcor, Vytorin, Zocor) phenytoin (Dilantin, Phenytek) pimozide (Orap) phenobarbital (Luminal) efavirenz (Atripla, Sustiva) triazolam (Halcion) orally administered midazolam rifampin (Rifadin, Rifamate, Rifater, Rimactane) St. John s wort ergot derivatives (ergotamine [Cafergot, Ergomar, Medihaler, Migergot, Wigraine, Wigrettes], dihydroergotamine [D.H.E. 45, Migranal], ergonovine [Ergotrate], methylergonovine [Methergine]) ethinyl estradiol-containing medications (eg, Lo Loestrin Fe, Ortho Tri-Cyclen Lo, Ortho Evra, NuvaRing) sildenafil or Revatio when used for the treatment of pulmonary arterial hypertension (PAH) None of the above Page 4 of 5
5 Technivie without ribavirin 47. Does the patient have a history of intolerance to ribavirin? Yes No 48. Does the patient have documented anemia? Yes No 49. What is the patient s baseline hemoglobin level? g/dl 50. Is the patient ineligible to receive ribavirin? Yes No If Yes, document reason for ribavirin ineligibility: Section H: Daklinza + Sovaldi 51. Will the patient be receiving treatment with a strong inducer of CYP3A (e.g., phenytoin, carbamazepine, St. John s wort)? Yes No 52. Does the prescribed daily dose of Daklinza exceed 60 mg? Yes No 53. Does the patient need to take Daklinza concurrently with a moderate CYP3A inducer (e.g., bosentan, dexamethasone, efavirenz, etravirine, modafinil, nafcillin, rifapentine)? Yes No Section I: Continuation of Therapy (Required for continuation of Victrelis or Olysio + PEG-IFN + ribavirin) 54. Document the following where applicable: A) Treatment week B) HCV-RNA Level (IU/mL Only) C) Date (to be) Completed Week 4 IU/mL Undetectable / / Week 8 IU/mL Undetectable / / Week 12 IU/mL Undetectable / / Week 24 IU/mL Undetectable / / Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor. X Prescriber or Authorized Signature Date (mm/dd/yy) OFFICE CONTACT: PHONE: EXT: Page 5 of 5
Hepatitis C (Direct Acting Antiviral Medications for Treatment of Hepatitis C) QUEST Integration Formulary
Hepatitis C (Direct Acting Antiviral Medications for Treatment of Hepatitis C) QUEST Integration Formulary Policy Number: Original Effective Date: MM.04.036 06/01/2015 Lines of Business: Current Effective
More informationREQUEST FOR PRIOR AUTHORIZATION Hepatitis C Treatments
Fax completed form to: 866-940-7328 Prior Authorization Phone Number: 800-310-6826 IA Medicaid Member ID # Patient name Date of Birth Patient address Patient phone Provider NPI Prescriber name Phone Prescriber
More informationAmeriHealth Caritas Iowa Request for Prior Authorization Hepatitis C Treatments
Form applies to IA Health Link and hawk-i plans. Please print accuracy is important. Fax completed form to 1-855-825-2714. Provider Help Desk: 1-855-328-1612. AmeriHealth Caritas Iowa member ID #: Patient
More informationState of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT
State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT HCV Phone: 1-888-445-0497 www.mainecarepdl.org Fax: 1-888-879-6938 Member ID #: Patient
More informationState of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT
State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT HCV Phone: 1-888-445-0497 www.mainecarepdl.org Fax: 1-888-879-6938 Member ID #: Patient
More informationWho should not take STRIBILD? Do not take STRIBILD if you also take a medicine that contains:
Patient Information STRIBILD (STRY-bild) (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) Tablets Important: Ask your healthcare provider or pharmacist about medicines that
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationHepatitis C Medications Hawaii PRIOR AUTHORIZATION REQUEST FORM
Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form contains multiple pages. Please complete all pages to avoid a delay in our decision.
More informationJOHNS HOPKINS HEALTHCARE
JOHNS HOPKINS HEALTHCARE Subject: Clinical Criteria for Hepatitis C (HCV) Therapy Department: Pharmacy Lines of Business: PPMCO Policy Number: MEDS92 Effective Date: 04/15/2015 Revision Date: 08/15/2015
More informationAddress: City: State: ZIP code: Inferferon Product Requested (Include Strength):
Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form contains multiple pages. Please complete all pages to avoid a delay in our decision.
More informationINFECTIOUS DISEASE AGENTS: HEPATITIS C - DIRECT - ACTING ANTIVIRAL
Ohio Department of Medicaid Prior Authorization Form Unified PDL HEPATITIS C TREATMENT Member ID# Patient Name: DOB: Patient Address: Provider DEA: Provider NPI: Provider Name: Phone: Provider Address:
More informationRibavirin (Medicare Prior Authorization)
Prior Authorization Form ARKANSAS BLUE CROSS AND BLUE SHIELD Medi-Pak Rx (PDP), Medi-Pak Advantage (PFFS), and Medi-Pak Advantage PPO Ribavirin (Medicare Prior Authorization) This fax machine is located
More informationZepatier (Elbasvir/Grazoprevir) Information Packet
Zepatier (Elbasvir/Grazoprevir) Information Packet Liver Disease & Hepatitis Program Providers: Brian McMahon, MD; Youssef Barbour, MD; Lisa Townshend-Bulson, FNP-C; Annette Hewitt, FNP-C; Stephen Livingston,
More informationTREATMENT BROCHURE DISCOVER YOUR WISDOM WITHIN
TREATMENT BROCHURE { DISCOVER YOUR WISDOM WITHIN Wisdom inspired by real people YOUR JOURNEY STARTS HERE Wisdom is in all of us and all around us. Learning from wisdom inspired by experts, healthcare providers,
More informationZepatier (Elbasvir/Grazoprevir) Treatment Agreement
Zepatier (Elbasvir/Grazoprevir) Treatment Agreement Liver Disease & Hepatitis Program Providers: Brian McMahon, MD; Youssef Barbour, MD; Lisa Townshend-Bulson, FNP-C; Annette Hewitt, FNP-C; Prabhu Gounder,
More informationOmbitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak) Prepared by: Sophie Woolston, MD and David H. Spach, MD Last Updated: December 29, 2014 OMBITASVIR-PARITAPREVIR-RITONAVIR
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationHepatitis B Agents Hepatitis C First Generation Agents Prior Authorization Through Preferred Agent(s) Criteria Program Summary
Hepatitis B Agents Hepatitis C First Generation Agents Prior Authorization Through Preferred Agent(s) Criteria Program Summary This program contains Incivek, Olysio, Pegasys, PegIntron, and Victrelis.
More informationPharmacy Medical Necessity Guidelines: Hepatitis C Virus
Pharmacy Medical Necessity Guidelines: Hepatitis C Virus Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX)
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationViekira Pak (Ombitasvir/Paritaprevir/Ritonavir; Dasabuvir) or Viekira XR (Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir) & Ribavirin Treatment Agreement
Viekira Pak (Ombitasvir/Paritaprevir/Ritonavir; Dasabuvir) or Viekira XR (Dasabuvir/Ombitasvir/Paritaprevir/Ritonavir) & Ribavirin Treatment Agreement Liver Disease & Hepatitis Program Providers: Brian
More informationPATIENT INFORMATION. REYATAZ (RAY-ah-taz) (atazanavir) capsules
REYATAZ (RAY-ah-taz) (atazanavir) capsules PATIENT INFORMATION REYATAZ (RAY-ah-taz) (atazanavir) oral powder Important: Ask your healthcare provider or pharmacist about medicines that should not be taken
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More informationHepatitis C Medications Prior Authorization Criteria
Hepatitis C Medications Authorization Criteria Epclusa (/velpatasvir), Harvoni (ledipasvir/), Sovaldi (), Daklinza (daclatasvir), Zepatier (elbasvir/grazoprevir), Olysio (simeprevir), Viekira Pak (ombitasvir/paritaprevir/ritonavir;
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis B / Hepatitis C Peg-interferon Page 1 of 20 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis B / Hepatitis C Peg-interferon Hepatitis
More informationSovaldi Ribavirin. Sovaldi (sofosbuvir) with Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Sovaldi Ribavirin Page: 1 of 7 Last Review Date: December 3, 2015 Sovaldi Ribavirin Description
More informationDaclatasvir (Daklinza ) Drug Interactions with HIV Medications
Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir
More informationOlysio PegIntron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.27 Subject: Olysio PegIntron Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio PegIntron
More informationOlysio Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio Pegasys
More informationPEGINTRON (peginterferon alfa-2b) SECTION 1: Pegintron - Hepatitis C Monotherapy
SECTION 1: Hepatitis C Pegintron SECTION 2: Hepatitis C Pegintron & Ribavirin SECTION 3: Hepatitis C Pegintron, Ribavirin, & Sovaldi SECTION 4: Hepatitis C Pegintron, Ribavirin, & Olysio SECTION 1: Pegintron
More informationDaklinza (Daclatasvir) & Sovaldi (Sofosbuvir) Treatment Agreement
Daklinza (Daclatasvir) & Sovaldi (Sofosbuvir) Treatment Agreement Liver Disease & Hepatitis Program Providers: Brian McMahon, MD; Youssef Barbour, MD; Lisa Townshend-Bulson, FNP-C; Annette Hewitt, FNP-C;
More informationOutpatient Pharmacy Effective Date: August 15, 2014
Therapeutic Class Code: W5Y, W5V, W0B, W0D, W0A, W0E Therapeutic Class Description: Hepatitis C Virus nucleotide analog NS5B RNA Dependent Polymerase Inhibitor, Hepatitis C Virus NS3/4A Serine Protease
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other TELAPREVIR INCIVEK 37629 This drug requires a written request for prior authorization. All requests for hepatitis C medications require review by a pharmacist prior
More informationPrior Approval Criteria Hepatitis C Virus Medications DRAFT
Therapeutic Class Code: W5Y, W5V, W0B, W0D, W0A, W0E Therapeutic Class Description: Hepatitis C Virus nucleotide analog NS5B RNA Dependent Polymerase Inhibitor, Hepatitis C Virus NS3/4A Serine Protease
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other SOFOSBUVIR/VELPATASVIR EPCLUSA TBD CUSTOMER SERVICE REPRESENTATIVE (CSR) If the member lives in Rhode Island or if the prescribing physician
More informationCriteria for Indiana Medicaid Hepatitis C Agents
Prepared for State of Indiana by OptumRx EXECUTIVE SUMMARY Purpose: Promote prudent prescribing of Setting & Population: All members Type of Criteria: Increased Risk of ADE Non-Preferred Agent Appropriate
More informationPegylated Interferon Agents for Hepatitis C
Applicable X X X X X X X Pegylated Interferon Agents for Hepatitis C Override(s) Prior Authorization Quantity Limit Initial for Monotherapy or Combination with Ribavirin based on Genotype, Status, or Co-Infection
More informationPatient Assistance Program
Patient Assistance Program Application INDICATION 1 VIEKIRA XR (dasabuvir, ombitasvir, paritaprevir, and ritonavir) extended-release tablets are indicated for the treatment of adult patients with chronic
More informationCircle Yes or No Y N. [If yes, skip to question 13 REAUTHORIZATION REQUESTS]
04/30/2014 Prior Authorization AETA BETTER HEALTH OF ILLIOIS MEDICAID Peginterferon (IL88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationMolina Healthcare of Texas Hepatitis C Drugs (Medicaid)
Texas Standard Prior Authorization Form Addendum Molina Healthcare of Texas Hepatitis C Drugs (Medicaid) This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review
More informationMEDICAL POLICY EFFECTIVE DATE: 9/1/2016 REVISED DATE: 1/1/2017
Page 1 of 19 DESCRIPTION: Hepatitis C Drug Coverage Criteria For all Regimens (see individual drugs for drug specific requirements). Based upon our assessment of the peer-reviewed literature, the drugs
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
DIRECT ACTING ANTIVIRAL AGENTS FOR HEPATITIS C VIRUS (HCV): DAKLINZA (daclatasvir) oral tablet EPCLUSA (velpatasvir, sofosbuvir) oral tablet HARVONI (ledipasvir, sofosbuvir) oral tablet MAVYRET (glecaprevir,
More informationTechnivie. Technivie (ombitasvir, paritaprevir, ritonavir) and Ribavirin. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Technivie Page: 1 of 6 Last Review Date: March 18, 2016 Technivie Description Technivie (ombitasvir,
More informationHarvoni (Ledipasvir/Sofosbuvir) Information Packet
Harvoni (Ledipasvir/Sofosbuvir) Information Packet Family Medicine Provider: If you are considering hepatitis C treatment, please read this treatment agreement carefully and be sure to ask any questions
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PART III: PATIENT MEDICATION INFORMATION. (daclatasvir tablets)
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PART III: PATIENT MEDICATION INFORMATION Pr DAKLINZA (daclatasvir tablets) Read this carefully before you start taking DAKLINZA and each time you get
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More informationSovaldi (sofosbuvir) with PegIntron (peginterferon alfa-2b) and Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.24 Subject: Sovaldi PegIntron Ribavirin Page: 1 of 6 Last Review Date: November 30, 2018 Sovaldi PegIntron
More informationInfergen (interferon alfacon-1) with Ribavirin (Copegus, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.04 Subject: Infergen with Ribavirin Page: 1 of 8 Last Review Date: March 13, 2014 Infergen with Ribavirin
More informationHIV and HCV Drug Interactions Cased Based Discussion. John J. Faragon, PharmD, BCPS, AAHIV-P. Brief background on HCV and HIV Coinfection
HIV and HCV Drug Interactions Cased Based Discussion John J. Faragon, PharmD, BCPS, AAHIV-P Roadmap Brief background on HCV and HIV Coinfection Revised AASLD Guidelines Case evaluating drug interactions
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 30 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationDATE: 6/03 LAST REVIEW DATE:
SUBJECT: Chronic Hepatitis C (Pegasys, Peg-Intron, ribavirin, Olysio, Sovaldi, Harvoni, ledipasvir/sofosbuvir, Viekira, Viekira XR, Daklinza, Technivie, Zepatier, Epclusa, sofosbuvir/velpatasvir, Vosevi,
More informationHepatits C Criteria Direct Acting Antiviral Medications
Hepatits C Criteria Direct Acting Antiviral Medications Harvoni-Formulary PA required 1. Is the patient being treated for a funded condition by the Oregon Health Plan? 2. Does the member have a diagnosis
More informationInfergen Monotherapy. Infergen (interferon alfacon-1) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.03 Subject: Infergen Monotherapy Page: 1 of 7 Last Review Date: March 13, 2014 Infergen Monotherapy
More informationHepatitis C (Direct Acting Antiviral Medications for Treatment of Hepatitis C) Fibrosis Score Requirement QUEST Integration
Hepatitis C (Direct Acting Antiviral Medications for Treatment of Hepatitis C) Fibrosis Score Requirement QUEST Integration Policy Number: Original Effective Date: MM.04.036 06/01/2015 Lines of Business:
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr KALETRA Tablets lopinavir/ritonavir This leaflet is PART III of a three-part Product Monograph published when KALETRA was approved for sale in Canada and is designed specifically
More informationSubject: Hepatitis C Drug Therapy
09-J0000-53 Original Effective Date: 01/01/06 Reviewed: 07/11/18 Revised: 11/15/18 Subject: Hepatitis C Drug Therapy THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 7 Last Review Date: June 24, 2016 Daklinza Sovaldi Description Daklinza
More informationUpdated Guidelines for Managing HIV/HCV Co-Infection
Updated Guidelines for Managing HIV/HCV Co-Infection John J Faragon, PharmD, BCPS, AAHIV-P Regional Pharmacy Director, NY/NJ AIDS Education and Training Center Pharmacist, HIV Medicine, Albany Medical
More informationOlysio Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 8 Last Review Date: December 18, 2017 Olysio Pegasys
More informationZepatier. Zepatier (elbasvir, grazoprevir) and Ribavirin. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Zepatier Page: 1 of 6 Last Review Date: March 18, 2016 Zepatier Description Zepatier (elbasvir,
More informationRecommended dosing for pediatric patients (6 months to 12 years of age) 1. Dose based on lopinavir component* 1.25 ml ml
Abbott Virology 100 Abbott Park Road Abbott Park, IL 60064 KALETRA 100/25 mg tablets NDC #0074-0522-60 Dear Healthcare Provider: Introducing a new strength of KALETRA (lopinavir/ritonavir): 100/25 mg tablets
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationClinical Policy: Daclatasvir (Daklinza) Reference Number: ERX.SPMN.180
Clinical Policy: (Daklinza) Reference Number: ERX.SPMN.180 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationZepatier is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh B or C) due to potential toxicity (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Zepatier Page: 1 of 6 Last Review Date: June 24, 2016 Zepatier Description Zepatier (elbasvir,
More information/ / Please provide contact information and indicate ONE method of preferred contact for notification of the results: me at:
Please note that the patient AND physician must complete this form. All fields are mandatory and must be completed. Incomplete forms may result in your application being declined. Please retain a copy
More informationVosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) Information Packet
Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) Information Packet Family Medicine Provider: If you are considering hepatitis C treatment, please read this treatment agreement carefully and be sure to ask
More informationZepatier. (elbasvir, grazoprevir) New Product Slideshow
Zepatier (elbasvir, grazoprevir) New Product Slideshow Introduction Brand name: Zepatier Generic name: Elbasvir, grazoprevir Pharmacological class: HCV NS5A inhibitor + HCV NS3/4A protease inhibitor Strength
More informationMAVYRET (glecaprevir, pibrentasvir ) NEW PRODUCT SLIDESHOW
MAVYRET (glecaprevir, pibrentasvir ) NEW PRODUCT SLIDESHOW Introduction Brand name: Mavyret Generic name: Glecaprevir, pibrentasvir Pharmacological class: HCV NS3/4A protease inhibitor + HCV NS5A inhibitor
More informationHolkira Pak (dasabuvir + ombitasvir/ paritaprevir/ritonavir)
FACTSHEET Holkira Pak (dasabuvir + ombitasvir/ paritaprevir/ritonavir) Summary Holkira Pak is a medication used to treat Hep C. Holkira Pak is a combination of dasabuvir, ombitasvir and paritaprevir boosted
More informationClinical Policy: Dasabuvir/ombitasvir/paritaprevir/ritonavir (Viekira XR, Viekira Pak) Reference Number: ERX.SPMN.178
Clinical Policy: (Viekira XR, Viekira Pak) Reference Number: ERX.SPMN.178 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy
More informationHepatitis C Treatment Checklists
Hepatitis C Treatment Checklists Prior to Treatment Labs: Immediately prior: Pregnancy test (if applicable) Uric Acid (only with ribavirin) Within 1 month: CBC with differential CMP 1 PT/INR HCV RNA Within
More informationPart I. Prior Authorization Criteria and Policy
Texas Vendor Drug Program Antiviral Agents for Hepatitis C Virus Initial Authorization Request (Medicaid) Part I. Prior Authorization Criteria and Policy March 2018-E I. Eligibility 1. Patient is enrolled
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.36 Subject: Daklinza Page: 1 of 8 Last Review Date: March 18, 2016 Daklinza Description Daklinza (daclatasvir)
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationClinical Policy: Daclatasvir (Daklinza) Reference Number: CP.CPA.283 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Daklinza) Reference Number: CP.CPA.283 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationClinical Policy: Elbasvir/grazoprevir (Zepatier) Reference Number: ERX.SPMN.181
Clinical Policy: (Zepatier) Reference Number: ERX.SPMN.181 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationTreatment of Hepatitis C with sofosbuvir/ledipasvir (Harvoni )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationTechnivie. Technivie (ombitasvir, paritaprevir, ritonavir) and Ribavirin. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.37 Subject: Technivie Page: 1 of 6 Last Review Date: December 8, 2017 Technivie Description Technivie
More informationClinical Policy: Daclatasvir (Daklinza) Reference Number: HIM.PA.SP27 Effective Date: Last Review Date: 06.18
Clinical Policy: (Daklinza) Reference Number: HIM.PA.SP27 Effective Date: 01.01.17 Last Review Date: 06.18 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: December 2, 2016 Harvoni Description Harvoni (ledipasvir
More information/ / Please provide contact information and indicate ONE method of preferred contact for notification of the results: me at:
Please note that the patient AND physician must complete this form. All fields are mandatory and must be completed. Incomplete forms may result in your application being declined. Please retain a copy
More informationHepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18
Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Overview Hepatitis C Virus Prevalence Effects of Hepatitis C Prevention Diagnosis
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationDaclatasvir (Daklinza)
Daclatasvir (Daklinza) Summary Daclatasvir (Daklinza) is a medication used to treat hepatitis C. It is taken with sofosbuvir (Sovaldi) and sometimes ribavirin. This combination is approved in Canada for
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2052-10 Program Prior Authorization/Medical Necessity Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 4/2015, 8/2015,
More informationreduce the amount of HIV-1 in your blood. This is called viral load.
Advise patients not to share personal items that can have blood or body fluids on them, like toothbrus hes and razor blades. Always practice safer sex by using a latex or polyurethane condom to lower the
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PART III: PATIENT MEDICATION INFORMATION. ombitasvir/paritaprevir/ritonavir tablets
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PART III: PATIENT MEDICATION INFORMATION Pr TECHNIVIE (pronounced TEK-ni-vee) ombitasvir/paritaprevir/ritonavir tablets Read this carefully before
More informationSimeprevir (Galexos)
FACTSHEET Simeprevir (Galexos) Summary Simeprevir is a medication used to treat Hep C. It is used in combination with other medications to cure people of the Hep C virus. It is approved in Canada for people
More informationClinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: GA.PMN.24 Product: Medicaid Effective Date: 9/17
Clinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: GA.PMN.24 Product: Medicaid Effective Date: 9/17 Last Review Date: 9/17 Revision Log See Important Reminder at the end of this policy
More informationPegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.08 Subsection: Anti-infective Agents Original Policy Date: January 1, 2006 Subject: Pegasys Ribavirin
More informationPharmacologic Considerations of HCV Treatment. Autumn Zuckerman, PharmD, BCPS, AAHIVP
Pharmacologic Considerations of HCV Treatment Autumn Zuckerman, PharmD, BCPS, AAHIVP Objectives Review pharmacokinetic properties of currently utilized Hepatitis C medications Review drug interactions
More informationSovaldi (sofosbuvir) with Pegasys (peginterferon alfa-2a) and Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.25 Subject: Sovaldi Pegasys Ribavirin Page: 1 of 6 Last Review Date: December 8, 2017 Sovaldi Pegasys
More informationClinical Policy: Ledipasvir/Sofosbuvir (Harvoni) Reference Number: CP.PHAR.279
Clinical Policy: (Harvoni) Reference Number: CP.PHAR.279 Effective Date: 09/16 Last Review Date: 05/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationDaclatasvir (Daklinza)
FACTSHEET Daclatasvir (Daklinza) Summary Daclatasvir (Daklinza) is a medication used to treat hepatitis C. It is taken with sofosbuvir (Sovaldi) and sometimes ribavirin. This combination is approved in
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 20 Last Review Date: March 16, 2018 Hepatitis C Agents Description
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 19 Last Review Date: December 8, 2017 Hepatitis C Agents
More informationTreatment of Hepatitis C with simeprevir (Olysio ) PLUS sofosbuvir (Sovaldi ) Archived Medical Policy
Treatment of Hepatitis C with simeprevir (Olysio ) PLUS sofosbuvir (Sovaldi ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More information